Quality of Life and Side Effects Management in Cancer Treatment (3rd Edition)

Dear Colleagues,

This Special Issue is the Third Edition of a previous Special Issue, titled “Quality of Life and Side Effects Management in Cancer Treatment” (link 1: https://www.mdpi.com/journal/cancers/special_issues/Quality_Effects_Cancer_Treatment; link 2: https://www.mdpi.com/journal/cancers/special_issues/35Y41G0VUJ).

In recent years, cancer treatment has evolved in ways previously unimaginable, giving our patients an increased rate of progression-free and/or overall survival. However, most importantly, these new drugs and new drug combinations are more patient-friendly, increasing quality of life. Nevertheless, we still have to learn how to control the adverse events that occur in target therapy and immunotherapy, and with the new drugs of hormonotherapy.

At present, we still struggle with these adverse events when combining different drugs for immunotherapy, immunotherapy with chemotherapy, or immunotherapy with target agents. Nausea and emesis induced by chemotherapy are still stressful events that we continually try to control; additionally, immune-mediated toxicity, rashes, and diarrhea induced by target therapy, and the numerous forms of pain that affect most of our cancer patients, are all still of significant concern and are the object of investigation.

We are, therefore, pleased to invite you to contribute to this Special Issue highlighting the current state of the art in the control of cancer treatments’ adverse events and in improving the quality of care for cancer patients, as well as featuring future prospects for improving therapies.

Prof. Dr. António Araújo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.